Retatrutide

Retatrutide Dosage Chart — Complete Research Protocol & Titration Guide

---

What Is Retatrutide?

Retatrutide is an investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly and currently in late-stage Phase 3 clinical development. Peptides UK

Unlike single or dual receptor agonists currently available for research, retatrutide acts on three hormone pathways simultaneously — one pathway helps the body feel full, one helps it handle blood sugar and stored fuel, and one may push energy use up — making it a uniquely comprehensive metabolic research compound. Peptidedosingprotocols

For researchers already working with compounds in our peptide sciences catalog, retatrutide represents the most advanced metabolic peptide currently under clinical investigation — and understanding the retatrutide dosage chart is the critical first step to designing accurate, reproducible research protocols.

---

Retatrutide Dosage Chart — Full Weekly Titration Schedule

The retatrutide dosage chart below summarizes the classic dosage tiers studied during Phase 2 dose-ranging trials. Note that 9mg and 12mg are now the Phase 3 validated doses from the TRIUMPH program, while 1mg, 4mg, and 8mg remain Phase 2 research reference points. parahealth

An important aspect of the retatrutide dosage chart is understanding that a higher dose does not automatically mean better results — clinical records show that even a 1mg dose already produces meaningful early response in research models. parahealth

For further reference on titration protocols visit PubMed — Jastreboff et al. NEJM 2023 and the NIH clinical trials database.

---

How Does Retatrutide Work?

Retatrutide is a triple-agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — the same general GLP-1 pathway used by semaglutide but with two additional receptor mechanisms layered on top, making it a considerably broader metabolic research compound. Remy Peptides

The 2mg starting dose in the retatrutide dosage chart is not therapeutic in terms of weight loss outcome — its purpose is to allow the GI tract to adapt to triple receptor activation before higher plasma concentrations arrive. This makes adherence to the full titration schedule critical for accurate and reproducible research outcomes. PeptideDeck

For researchers coming from GLP-1 work explore our related peptide therapy near me page and anti-aging peptides catalog for complementary metabolic research compounds.

---

Phase 3 TRIUMPH Trial Data

TRIUMPH-4 evaluated 9mg and 12mg maintenance doses and reported 28.7% weight loss at 68 weeks — the Phase 3 data confirming that the weight-loss signal seen in Phase 2 scales with longer exposure and higher doses. PeptideDeck

Key TRIUMPH Phase 3 findings relevant to the retatrutide dosage chart:

• 9mg maintenance dose — Phase 3 validated primary maintenance arm
• 12mg maintenance dose — Phase 3 validated maximum maintenance arm
• 28.7% mean weight reduction — reported at 68 weeks in TRIUMPH-4
• Dysesthesia signal — abnormal skin sensations such as tingling or burning, a novel finding specific to retatrutide likely linked to glucagon receptor activation, generally mild and rarely leading to treatment discontinuation PeptideDeck
• Dosing interval — once weekly subcutaneous administration throughout all trial phases

For full TRIUMPH trial data reference visit ClinicalTrials.gov — Retatrutide TRIUMPH and Eli Lilly Pipeline Research.

---

Retatrutide Dosage Chart — Research Protocol Notes

Beginners should follow the conservative titration path in the retatrutide dosage chart and should not skip dose levels regardless of perceived tolerance — faster escalation dramatically increases the rate of GI side effects and protocol dropout. PeptideDeck

Key protocol notes for researchers using this dosage chart:

• Starting dose — 1mg once weekly for the first 4 weeks minimum
• Escalation interval — increase dose every 4 weeks maximum
• Missed dose protocol — if fewer than 4 days have elapsed administer as soon as possible; if more than 4 days have passed skip that dose and resume the regular schedule Remy Peptides
• Half-life — approximately 6 days supporting once-weekly dosing intervals
• Storage — lyophilized powder stored at −20°C; reconstituted material at 2–8°C

See our full peptide storage and handling guide for complete reconstitution and storage protocols.

---

Sourcing Research-Grade Retatrutide

When sourcing retatrutide for research, look for vendors that provide independent third-party HPLC testing, mass spectrometry confirmation, and a Certificate of Analysis from a US-based or internationally accredited laboratory. Purity should be ≥98%. PeptideDeck

Every retatrutide compound in our catalog meets these standards — independently verified, fully documented, and supplied exclusively for qualified research use. Browse our complete research peptides catalog for full product specifications and current availability.

---

Product Specifications

For safety data and handling protocols visit the U.S. National Library of Medicine or our peptide storage and handling guide.

---

Disclaimer

Retatrutide is an investigational compound and is not approved by the FDA or any regulatory authority for human or veterinary use as of May 2026. This retatrutide dosage chart is provided strictly as a research reference based on published Phase 2 and Phase 3 clinical trial data. It does not constitute medical advice, a treatment plan, or a recommendation for human use outside of an authorized clinical trial. For full regulatory guidance visit FDA Research Use Guidelines.

---

Frequently Asked Questions About Retatrutide Dosage Chart

---

Q1: What is the retatrutide dosage chart?

The retatrutide dosage chart summarizes the weekly titration schedule studied across Phase 2 and Phase 3 clinical trials, ranging from a 1mg starting dose up to a 12mg validated maintenance dose in the TRIUMPH program. Learn more on our peptide sciences homepage. parahealth

---

Q2: What is the starting dose on the retatrutide dosage chart?

The recommended retatrutide starting dose is 1mg per week for the first 4 weeks — this beginner dose allows the digestive system to adapt before escalation and should not be skipped regardless of perceived tolerance. See our research peptides catalog for product availability. PeptideDeck

---

Q3: What are the Phase 3 validated doses?

9mg and 12mg are the Phase 3 validated doses from the TRIUMPH program, while 1mg, 4mg, and 8mg remain Phase 2 research reference points. Full TRIUMPH data is available at ClinicalTrials.gov. parahealth

---

Q4: How often is retatrutide dosed?

Retatrutide is an investigational once-weekly compound and the Phase 3 dosing framework is a stepwise titration protocol, not a single fixed dose. The approximately 6-day half-life supports this once-weekly administration interval throughout the entire research protocol. Peptidedosingprotocols

---

Q5: What TRIUMPH trial results are relevant to the dosage chart?

TRIUMPH-4 reported 28.7% weight loss at 68 weeks at the 9mg and 12mg maintenance doses, confirming that the weight-loss signal seen in Phase 2 scales with longer exposure and higher doses. See full data at ClinicalTrials.gov. PeptideDeck

---

Q6: What happens if a dose is missed?

If a scheduled weekly dose is missed and fewer than 4 days have elapsed, administer as soon as possible. If more than 4 days have passed, skip that dose and administer the next dose on the regular schedule — the titration timeline is not reset for a single missed dose. Remy Peptides

---

Q7: What is the purity standard for research-grade retatrutide?

When sourcing retatrutide for research, purity should be ≥98% confirmed by independent third-party HPLC testing and mass spectrometry with a Certificate of Analysis from an accredited laboratory. View our quality assurance process for full verification details. PeptideDeck

---

Q8: How is retatrutide stored?

Store in lyophilized powder form at −20°C to maintain full stability. Once reconstituted refrigerate at 2–8°C and use within the recommended timeframe. See our peptide storage guide or NIH compound storage guidelines.

---

Q9: How does retatrutide compare to semaglutide dosing?

Retatrutide is a triple-agonist dosed from 2mg to 12mg per week, while semaglutide is a single GLP-1 agonist dosed from 0.25mg to 2.4mg per week — retatrutide uses a 4-week escalation interval versus semaglutide’s faster titration schedule. Compare metabolic research compounds in our peptide blends catalog. Remy Peptides

---

Q10: Is retatrutide legal to purchase for research?

Retatrutide is an investigational compound not licensed for human or veterinary use by the FDA, EMA, or MHRA as of 2026. The only legal access route for human use is participation in an authorized clinical trial. It is available for legitimate laboratory and research use only. For full guidance visit FDA Research Use Guidelines. Peptides UK